CASE PRESENTATION
=================

A 30-year-old Caucasian man presented to the pulmonary function laboratory for a pulmonary function test (PFT) and methacholine challenge test. The patient's chief complaint was dyspnea with exercise. He had never smoked but worked as an electrician, often in dusty environments. The patient reported a family history of asthma among two of his siblings. Measured height and weight on the day of testing indicated a body mass index of 28.1 kg/m^2^. Baseline PFT data are summarized in [Table 1](#t1-cjrt-52-2-53){ref-type="table"}, the flow-volume loop and volume-time curve from spirometry are shown in [Figure 1](#f1-cjrt-52-2-53){ref-type="fig"}. All testing satisfied American Thoracic Society (ATS)/European Respiratory Society acceptability and repeatability quality standards ([@b1-cjrt-52-2-53]). Baseline spirometry suggested a restrictive ventilatory defect, which was confirmed by lung volume measurements via whole body plethysmography.

Following baseline testing, a methacholine challenge test was performed using the five-breath dosimeter technique ([@b2-cjrt-52-2-53]). Following inhalation of the final dose of methacholine (20 mg/mL), the forced expiratory volume in 1 s (FEV~1~) was 8% below baseline. Such a modest reduction in FEV~1~ would typically be regarded as a 'negative' methacholine challenge test; however, the patient complained of chest tightness and dyspnea. He reported that these symptoms were similar to those he experienced after running. There were no stridor or indications of inducible laryngeal obstruction. The patient's symptoms in the absence of a significant decline in FEV~1~ prompted repeat measurement of specific airway conductance (sGaw) as an alternative method to assess the airway response to methacholine inhalation. The sGaw was found to be 73% below baseline, indicating significant airway narrowing compatible with marked airway hyper-responsiveness. Following bronchodilator administration (2.5 mg albuterol via small volume nebulizer) both the FEV~1~ and sGaw values were larger than those recorded during baseline testing, suggesting a degree of pretest bronchoconstriction ([Table 2](#t2-cjrt-52-2-53){ref-type="table"}, [Figure 2](#f2-cjrt-52-2-53){ref-type="fig"}).

DISCUSSION
==========

The 1999 ATS guideline for methacholine challenge testing states that FEV~1~ should be the primary outcome measure for the discovery of airway hyper-responsiveness ([@b2-cjrt-52-2-53]). The guideline recognizes that alternative measures of pulmonary function (eg, sGaw, impulse oscillometry) may be used during a methacholine challenge test; however, these measures are recommended only when the patient can not produce high-quality spirometry data. A whole-body plethysmograph (often called a 'body box') is required to measure sGaw. The patient is asked to breathe small volumes at a rate of 1.5 breaths/s to 2.5 breaths/s. Flow at the mouth is plotted against the pressure inside the plethysmograph (ie, 'box pressure'). After the collection of several breaths, a shutter or valve is closed so that mouth (alveolar) pressure can be plotted against box pressure. This is accomplished by having the patient continue shallow breathing at a rate of approximately 1 breath/s. Following open and closed shutter breathing, mouth pressure can be divided by flow to calculate airway resistance. The reciprocal of resistance is conductance. Conductance values provide limited information because conductance shares a linear relationship with lung volume. sGaw is considered to be a more useful value because it represents the conductance adjusted to the lung volume where the measurement was recorded. In other words, the influence of lung volume on conductance is removed.

The ATS guideline recommends that a larger reduction in sGaw (eg, 45%) be used as a cut-off point for a 'positive' methacholine challenge test. Khalid et al ([@b3-cjrt-52-2-53]) evaluated sGaw and FEV~1~ in 138 patients undergoing a methacholine challenge test. The researchers found that a 51% to 52% reduction in sGaw was a more appropriate cut-off point for a positive methacholine challenge test than the 45% reduction suggested by the ATS. A remarkable finding was that 32 patients with an FEV~1~ decline \<20% exhibited a reduction in sGaw \>50%.

In a similar study, Parker and McCool ([@b4-cjrt-52-2-53]) measured FEV~1~ and sGaw following methacholine challenge testing in 248 consecutive patients with asthma-like symptoms. Forty patients showed a response to methacholine as assessed by sGaw (≥40% reduction) without a significant decline in FEV~1~ (\<20%). The obvious question that arises from these observations is whether using FEV~1~ as the sole outcome measure during methacholine challenge testing results in false-negative tests in some patients. In other words, does the positive sGaw/negative FEV~1~ response indicate asthma or an expected response in some nonasthmatic patients or both? Parker and McCool ([@b4-cjrt-52-2-53]) found that subjects with this response had a higher baseline sGaw and forced expiratory flow between 25% and 75% of the forced vital capacity (FEF~25--75~) to forced vital capacity ratio, suggesting that dysanapsis (large tracheobronchial tree compared with lung size) may be causal. The authors offered other possible mechanisms for the positive sGaw/negative FEV~1~ response including disproportionate proximal airway narrowing, differences in airway compliance and airway smooth muscle distribution.

Both studies used the five-breath dosimeter technique with inhalation of aerosol to total lung capacity. Cockcroft and Davis ([@b5-cjrt-52-2-53]) showed that this technique results in false-negative methacholine challenge tests as judged by FEV~1~ in patients with mild asthma. It is not clear whether sGaw and FEV~1~ are equally affected by the bronchodilatory and bronchoprotective effects of deep inhalation.

In addition to nonspecific airway challenge testing (eg, methacholine, histamine), Larbanois et al ([@b6-cjrt-52-2-53]) reported that 13% of patients undergoing specific inhalation challenge had a ≥50% decline in sGaw without a ≥20% decline in FEV~1~. Because sGaw is believed to be more reflective of large airway function ([@b7-cjrt-52-2-53]), the authors speculated that this pattern may, in part, be related to the site of aerosol deposition. Given the complexity of pulmonary structure and function in the realm of airway hyper-responsiveness ([@b8-cjrt-52-2-53]), the etiology of the positive sGaw/negative FEV~1~ response is likely multifactorial.

Whether one chooses to follow FEV~1~, sGaw or both, the inherent limitations of bronchial challenge tests must be appreciated to avoid misinterpretation and misdiagnosis. Methacholine challenge tests are not perfect, the sensitivity and specificity can be \<60% and 70%, respectively ([@b9-cjrt-52-2-53]). Methacholine challenge tests simply determine the presence of airway hyper-responsiveness to a nonspecific agent. The presence of airway hyper-responsiveness only increases the probability of asthma in patients with an intermediate or high pretest probability of asthma ([@b10-cjrt-52-2-53]). Therefore, methacholine challenge tests should not be used in isolation to diagnose asthma. It would also be incorrect to assume that every patient with a positive sGaw/negative FEV~1~ response to methacholine challenge testing has asthma. This would be especially suspect in patients with a low pretest probability of asthma. In the present case, however, the patient had an intermediate pretest probability of asthma due to his asthma-like symptoms and family history. The fact that the large reduction in sGaw during methacholine challenge testing was accompanied by familiar symptoms that he had experienced after exercise increases the post-test probability of asthma, even in the absence of a 20% reduction in FEV~1~.
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###### 

Baseline pulmonary function data

  **Parameter**          **Actual**   **LLN**   **Pred**   **% Pred**   **z-score**
  ---------------------- ------------ --------- ---------- ------------ -------------
  FVC, L                 3.87         4.05      5.03       77           −1.95
  FEV~1~, L              2.93         3.33      4.17       70           −2.40
  FEV~1~/FVC, %          76           72        83         NR           −1.16
  TLC~PLETH~, L          5.04         5.59      6.74       75           NR
  RV, L                  1.20         1.02      1.70       71           NR
  RV/TLC, %              23           21        26         88           NR
  sGaw, L/s/cm H~2~O/L   0.26         0.11      0.26       100          NR

FEV~1~ Forced expiratory volume in 1 s; FVC Forced vital capacity; LLN Lower limit of normal; NR Not reported; Pred Predicted value; RV Residual volume; RV/TLC Ratio of RV to total lung capacity (TLC); sGaw Specific airway conductance; TLC~PLETH~ TLC via plethysmography

###### 

Forced expiratory volume in 1s (FEV~1~) and Specific airway conductance (sGaw) before and after methacholine challenge testing (MCT)

                         **Baseline**   **Post MCT**   **Δ, %**   **Post BD**   **Δ, %**
  ---------------------- -------------- -------------- ---------- ------------- ----------
  FEV~1~, L              2.93           2.70           −8         3.14          +7
  sGaw, L/s/cm H~2~O/L   0.26           0.07           −73        0.33          +27

BD Bronchodilator
